AB CHECK
Live / Registered — Registered (as of 08 Aug 2023)
What this means for you
Registered since 08 Aug 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88073859
- Registration number
- 7133412
- Mark type
- Design + words
- Filed
- 10 Aug 2018
- Published for opposition
- 29 Sept 2020
- Registered
- 08 Aug 2023
- Attorney of record
- Karen L. Elbing
Goods and services
- Class 042 — Scientific and technological services: Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis; scientific and technological services and research projects for the identification and characterisation of binding molecules, namely, in the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation of chemical analyses; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, medical research in the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely, in the field of antibody discovery, antibody research and antibody optimization, namely, scientific research in the field of antibodies; scientific and technological services and research projects in relation to antibody discovery, namely, medical research in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely, medical research in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to screening of antibody libraries, namely, in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely, in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely, in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors in the nature of research and development services in the field of antibodies; scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely, scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely, scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely, scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to antibody development strategies, namely, scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely, in the field of antibody research and drug design; scientific and technological services and research projects in relation to multi-factor antibody optimization, namely, scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely, scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody technology, namely, scientific research in the field of antibody research and antibody optimization
Owner
- AbCheck s.r.o., Plzen, CZ
- AbCheck s.r.o., Plzen, CZ
- AbCheck s.r.o., Plzen, CZ
Prosecution history
- 08 Aug 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 08 Aug 2023 — REGISTERED-PRINCIPAL REGISTER
- 06 Jul 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 05 Jul 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 09 Jun 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Jun 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 08 Jun 2023 — SOU EXTENSION 5 GRANTED
- 24 May 2023 — SOU EXTENSION 5 FILED
- 24 May 2023 — USE AMENDMENT FILED
- 30 May 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 24 May 2023 — SOU TEAS EXTENSION RECEIVED
- 24 May 2023 — TEAS STATEMENT OF USE RECEIVED
- 01 Nov 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Oct 2022 — SOU EXTENSION 4 GRANTED
- 28 Oct 2022 — SOU EXTENSION 4 FILED